Flexion therapeutics – Flexion Therapeutics, Inc. Change in Control Severance Benefit Plan Approved by the Board of Directors on June 22, 2017 (June 23rd, 2017)
The Flexion Therapeutics, Inc. Change in Control Severance Benefit Plan (the Plan) is hereby established effective upon the date of approval by the Board of Directors of Flexion Therapeutics, Inc. (the Company) set forth above (the Effective Date). The purpose of the Plan is to provide for the payment of severance benefits to eligible employees of the Company in the event that such employees become subject to involuntary or constructive employment terminations in connection with a change in control. This Plan document also is the Summary Plan Description for the Plan.
Flexion therapeutics – FLEXION THERAPEUTICS, INC. AND WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of May 2, 2017 3.375% Convertible Senior Notes Due 2024 (May 2nd, 2017)
INDENTURE dated as of May 2, 2017 between Flexion Therapeutics, Inc., a Delaware corporation, as issuer (the Company, as more fully set forth in Section 1.01) and Wells Fargo Bank, National Association, a national banking association organized under the laws of the United States of America, as trustee (the Trustee, as more fully set forth in Section 1.01).
Flexion therapeutics – Consent and Second Amendment to Credit and Security Agreement (May 2nd, 2017)
CONSENT AND SECOND AMENDMENT TO CREDIT AND SECURITY AGREEMENT (this Agreement) is dated as of April 24, 2017, and is effective as of the Consent Effective Date (as defined in in Section 6), by and among FLEXION THERAPEUTICS, INC., a Delaware corporation (the Borrower), the financial institutions or other entities from time to time parties thereto as lenders (the Lenders), and MIDCAP FINANCIAL TRUST, a Delaware statutory trust (MidCap), as Agent (in such capacity, Agent).
Flexion therapeutics – Supply Agreement (March 10th, 2017)
This Supply Agreement ("Agreement") is made effective as of the 1st day of July, 2016 (the "Effective Date") by and between Evonik Corporation, an Alabama Corporation with its principal place of business at 299 Jefferson Road, Parsippany, New Jersey 07054 and with a facility at 750 Lakeshore Parkway, Birmingham, Alabama 35211 (hereinafter referred to as "Supplier") and Flexion Therapeutics, Inc. with its principal place of business at 10 Mall Road, Suite 301, Burlington, Massachusetts 01803 (hereinafter referred to as "Purchaser"). Supplier and Purchaser are sometimes referred to herein individually as a "Party" and collectively as the "Parties."
Flexion therapeutics – Fourth Amendment of Lease (August 3rd, 2016)
AGREEMENT ("Fourth Amendment") made this 29th day of June, 2016 by and between CIP II/RJK 10-20 BMR Owner, LLC, 55 Cambridge Street, Burlington, Massachusetts 01803 (hereinafter referred to as "Landlord") and Flexion Therapeutics, Inc. (hereinafter referred to as "Tenant").